Biocomposites, a global leader in medical devices for infection management in bone and soft tissue, has received expanded approval in India for its flagship product, STIMULAN Rapid Cure.

 

The Central Drugs Standard Control Organisation (CDSCO) has cleared the product for use with a broader range of antibiotics—including combinations—and, for the first time worldwide, with antifungals.

 

STIMULAN Rapid Cure, already approved in over 60 countries as the only calcium matrix that can be mixed with antibiotics for bone and soft tissue applications, now gives Indian surgeons unprecedented flexibility in treating infections and promoting wound healing.

 

Surgical site infections and antimicrobial resistance remain major challenges globally, contributing to increased mortality. With this approval, surgeons in India can now tailor antimicrobial treatments to the unique needs of each patient.

 

Michael Harris, CEO of Biocomposites, said: “This expanded approval for STIMULAN Rapid Cure will allow surgeons in India to tailor antimicrobial treatment strategies to their patients’ needs. STIMULAN Rapid Cure already helps more than 150,000 patients worldwide every year, and is an important tool for surgeons as they tackle the impact of antimicrobial resistance and help their patients.”

 

Biocomposites continues to lead in engineering, manufacturing, and marketing innovative solutions for infection management in bone and soft tissue worldwide, according to the company.